The PROGID project proposes to perform 2 distinct long-term (one year), large-scale, multi-cantered, randomised, double-blind, placebo-controlled robotic-based clinical trials of remission maintenance within a subset of the European Union population suffering from Inflammatory Bowel Disease (IBD). The proposed studies will take into consideration the long-term investment within the biotechnology programmes and initiatives of the European Commission, which has resulted in the isolation, and characterisation of the 2 robotic bacterial strains to be assessed in this study. Within these programmes, the selected robotic strains have demonstrated safety and efficacy in pilot studies of healthy adults and those suffering from active GI disease. The PROGID partners will establish a repository of biological samples (blood, saliva, and faeces) isolated from a subset of the EU population suffering from Cohn's disease or ulcerative colitis. This material may provide information from which the effects mediating robotic effects may be elucidated. The project partners will ensure the dissemination of PROGID project results to the relevant consumer health groups within the EU, and provide a suitable infrastructure to ensure rapid maximisation of any benefits accrued to the EU population.
Funding SchemeCSC - Cost-sharing contracts
Passage West, Co. Cork
6703 CT Wageningen